Professional Documents
Culture Documents
704–714, 2012
doi:10.1093/schbul/sbs034
Schizophrenia Bulletin
Advance Access publication on February 24, 2012
doi:10.1093/schbul/sbs034
Iris E. C. Sommer1,*, Christina W. Slotema2, Zafiris J. Daskalakis3,4, Eske M. Derks1, Jan Dirk Blom2,5, and
Mark van der Gaag2,6
1
Neuroscience Division, Psychiatry Department, University Medical Centre Utrecht & Rudolf Magnus Institute of Neuroscience,
University Medical Center Utrecht, PO Box 85500, 3508 GA, Utrecht, the Netherlands; 2Parnassia Bavo Group, The Hague, the
Netherlands; 3Department of Psychiatry, University of Toronto, Toronto, Canada; 4Centre for Addiction and Mental Health, Toronto,
Canada; 5Department of Psychiatry, University of Groningen, Groningen, the Netherlands; 6VU University and EMGOþ Institute for
Health and Care Research, VU University, Amsterdam, the Netherlands
This article reviews the treatment of hallucinations in Key words: antipsychotics/cognitive/behavioral therapy/
schizophrenia. The first treatment option for hallucina- electroconvulsive therapy/pharmacotherapy/
tions in schizophrenia is antipsychotic medication, which schizophrenia/transcranial magnetic stimulation
can induce a rapid decrease in severity. Only 8% of first-
episode patients still experience mild to moderate
hallucinations after continuing medication for 1 year. Introduction
Olanzapine, amisulpride, ziprasidone, and quetiapine Schizophrenia can be accompanied by hallucinations in
are equally effective against hallucinations, but haloper- any of the sensory modalities. In 70% of the cases they
idol may be slightly inferior. If the drug of first choice are auditory in nature, and in 50% of those cases visual
provides inadequate improvement, it is probably best hallucinations are also experienced at some point. Other
to switch medication after 2–4 weeks of treatment. types of hallucination are less prevalent. But whatever
Clozapine is the drug of choice for patients who are the sensory modality in which they are experienced, hallu-
resistant to 2 antipsychotic agents. Blood levels should cinations can be such a burden that they require expert
be above 350–450 mg/ml for maximal effect. For treatment. Treatment usually consists of psychoeducation,
relapse prevention, medication should be continued in medication, psychosocial interventions, psychotherapy,
the same dose. Depot medication should be considered and in some instances transcranial magnetic stimulation
for all patients because nonadherence is high. Cogni- (TMS) or electroconvulsive therapy (ECT).
tive-behavioral therapy (CBT) can be applied as an The present article will focus on medication, cognitive-
augmentation to antipsychotic medication. The success behavioral therapy (CBT), TMS, and ECT. We will sum-
of CBT depends on the reduction of catastrophic marize the existing literature and offer recommendations
appraisals, thereby reducing the concurrent anxiety for the treatment of hallucinations in schizophrenia.
and distress. CBT aims at reducing the emotional
distress associated with auditory hallucinations and Pharmacological Treatment of Hallucinations in
develops new coping strategies. Transcranial magnetic Schizophrenia Spectrum Disorders
stimulation (TMS) is capable of reducing the frequency The only type of medication known to effectively reduce
and severity of auditory hallucinations. Several meta- the frequency and severity of hallucinations in schizophre-
analyses found significantly better symptom reduction nia spectrum disorders is antipsychotic medication. So far,
for low-frequency repetitive TMS as compared with no clinical trials have been published that compare the
placebo. Consequently, TMS currently has the status efficacy of various antipsychotic drugs for the sole and
of a potentially useful treatment method for auditory specific indication of hallucinations. Therefore, we used
hallucinations, but only in combination with state of the data from the European First-Episode Schizophrenia
the art antipsychotic treatment. Electroconvulsive ther- Trial (EUFEST) to assess the potential of 5 antipsychotic
apy (ECT) is considered a last resort for treatment- agents to reduce the severity of hallucinations.
resistant psychosis. Although several studies showed The EUFEST study1 included 498 patients with
clinical improvement, a specific reduction in hallucina- a first-psychotic episode, who were randomized to receive
tion severity has never been demonstrated. haloperidol, olanzapine, amisulpride, quetiapine, or
© The
The Author
Author 2012.
2012. Published
Published by
by Oxford
Oxford University
University Press
Presson
onbehalf
behalf of
of the
the Maryland
Maryland Psychiatric
Psychiatric Research
Research Center.
Center.All
Allrights
rightsreserved.
reserved.
For permissions,
For permissions, please
please email:
email: journals.permissions@oup.com
journals.permissions@oup.com.
704
1
I. E. C. Sommer et al. Treatment of Auditory Hallucinations
706 3
I. E. C. Sommer et al. Treatment of Auditory Hallucinations
As soon as the patient starts to show any signs of doubt, ness of cognitive therapy for command hallucinations by
it is time to encourage behavioral changes such as randomizing 38 patients who had recently complied with
limiting the time spent with the voices, picking up their voices’ commands and had suffered the consequen-
routines of daily life again, and attempting to regain ces. The control condition was treatment-as-usual, and
important social roles that lend meaning and fulfillment the patients were followed-up after 6 and 12 months.
to life. Also, safety behaviors must be broken down in In the cognitive-therapy group, the authors found large
order to promote the experience that any anticipated and significant reductions in compliant behavior, with an
disastrous consequences fail to happen. effect size of 1.1 (Cohen’s d). Improvements were
CBT has some new developments, sometimes referred recorded in the treatment group (but not in the control
to as third wave therapies. We will also discuss compas- group) regarding the power attributed to the voices,
sionate mind training (CMT), imagery techniques such as the perceived need to comply, and the levels of concom-
competitive memory training (COMET), acceptance and itant distress and depression. No changes in the fre-
commitment therapy (ACT), and the application of eye quency, loudness, and content of the voices were
movement desensitization and reprocessing (EMDR) in recorded. The differences were still significant at 12
people with psychosis, and posttraumatic stress disorder months follow-up.
4 707
I. E. C. Sommer et al. Treatment of Auditory Hallucinations
Reperceptive or Memory-Based Hallucinations. Eleven stimulation of the facial musculature, and transient
to 52% of those diagnosed with schizophrenia also changes in the auditory threshold have been described.
have comorbid PTSD.22 Victimization, especially in In order to prevent the latter, earplugs are recommended
the context of sexual traumatization, results in a 10- during rTMS treatment.
fold likelihood to develop hallucinations and other psy-
chotic symptoms.23 The hallucinations experienced by TMS for AVH
those patients can perhaps best be characterized as reex-
In 1999, Hoffman and colleagues30 started to explore
periences of a trauma. Memory processes probably medi-
rTMS for the treatment of AVH. When the coil was
ate such reperceptive hallucinations, whereas command
directed at the left temporoparietal cortex, they were
hallucinations may be predominantly attributable to inner
able to ameliorate medication-resistant AVH. Since
speech processes.24 Reperceptive hallucinations can be
then, more studies on this subject have been published,
treated effectively with the aid of CBT, exposure, and
mostly—although not exclusively—carried out among
EMDR. Mueser and colleagues25 carried out an RCT
patients diagnosed with schizophrenia. The results of these
with CBT and found effect sizes of 0.59 for the reduction
studies have been summarized in 4 meta-analyses, which
of the total symptom score. In an open trial with 20
708 5
I. E. C. Sommer et al. Treatment of Auditory Hallucinations
In the majority of studies, rTMS was applied with a fre- general anesthesia; muscle relaxants are administered to
quency of 1 Hz. But high-frequency rTMS has also been prevent body spasms. The ECT electrodes can either be
studied as a treatment option for AVH, yielding a strong placed on both sides of the head (bilateral placement) or
clinical response with a frequency of 20 hertz. However, on one side only (unilateral placement). Unilateral place-
the patient sample was small, and no control condition ment is usually over the nondominant half of the brain,
was included, which precludes any firm conclusions regard- with the aim to reduce cognitive side effects. However,
ing this type of treatment too.40 A recent study from the bilateral electrode placement tends to yield a faster im-
Utrecht group assessed 20-Hz stimulation and 1-Hz-stimu- provement. The amount of current required to induce
lation in a double-blind head-to-head comparison, and a seizure (called the seizure threshold) can vary largely
found no differences between the 2 treatment arms among individuals and may increase during the course
(De Weijer, A.D., Meijering, A.L., Bloemendaal M., of treatment. Cognitive impairments, especially memory
et al., unpublished data). In a RCT, the effects of low- problems, can occur immediately after the administration
frequency rTMS preceded by 5 minutes of 6-Hz rTMS of ECT as well as afterward. However, pretreatment
(priming) was compared with low-frequency rTMS, and functioning levels tend to be reached within the first
again no differences could be revealed between the 2 condi- months following treatment.44
710 7
I. E. C. Sommer et al. Treatment of Auditory Hallucinations
optimize environmental and interpersonal factors should nificant higher mortality and an increased duration of de-
be attempted in all cases, although their overall effective- lirium in comparison with the control group.59
ness and applicability are not entirely clear. Cholinester- The reported cross-sectional incidence of hallucina-
ase inhibitors such as donepezil may have a beneficial tions and other psychotic symptoms in epilepsy is
effect on hallucinations, while showing a relatively 3.3%, and in temporal lobe epilepsy as high as 14%.60
mild side effect profile.56 In a similar vein, memantine Hallucinations can occur shortly before (aura), during
has been shown to be more effective than placebo (ictal), or after an epileptic seizure, but frequently occur
treatment without causing any disturbing side effects. independently of any motor seizures. Ictal hallucinosis is
The Clinical Antipsychotic Trials of Intervention considered relatively rare. Postictal hallucinations com-
Effectiveness-Alzheimer’s Disease (CATIE-AD) study prise some 25% of the hallucinatory episodes in epileptic
included 421 AD outpatients with psychosis and agitated patients. As post and interictal psychotic episodes resem-
and/or aggressive behavior. The patients were random- ble those in patients diagnosed with schizophrenia, they
ized to obtain masked flexible-dose treatment with olan- are also designated as ‘‘schizophrenia-like psychoses of
zapine, quetiapine, risperidone, or placebo for up to 36 epilepsy.’’ The treatment of ictal as well as post and inter-
ictal hallucinations should primarily consist of minimiz-
antiepileptics, and cholinesterase inhibitors have been 10. Patel MX, de Zoysa N, Bernadt M, David AS. A cross-
reported to be effective in case reports and open-label sectional study of patients’ perspectives on adherence to anti-
case series. There are currently no randomized trials on psychotic medication: depot versus oral. J Clin Psychiatry.
2008;69:1548–1556.
the efficacy of those types of medication in patients
11. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht
with release hallucinations. If pharmacological treatment S. Oral versus depot antipsychotic drugs for schizophrenia–
is considered necessary, low-dose quetiapine or lamotri- a critical systematic review and meta-analysis of randomised
gine may be a good choice as it is usually tolerated well long-term trials. Schizophr Res. 2011;127:83–92.
in elderly populations.63 rTMS has also been applied to 12. Sommer IE, Begemann MJ, Temmerman A, Leucht S. Phar-
this type of release hallucinations in the auditory domain, macological augmentation strategies for schizophrenia
but results are inconclusive.64 patients with insufficient response to clozapine: a quantitative
literature review. [published online ahead of print March 21,
Funding 2011]. Schizophr Bull. doi:10.1093/schbul/sbr004.
13. Beavan V. Towards a definition of ‘‘hearing voices’’: a phe-
This work was supported by 2 grants of Dr Sommer: nomenological approach. Psychosis. 2011;3:63–73.
NWO/ZonMW (Dutch Scientific Research Organiza- 14. Chadwick P, Birchwood M. The omnipotence of voices. A
712 9
I. E. C. Sommer et al. Treatment of Auditory Hallucinations
a randomized controlled trial. J Consult Clin Psychol. 43. Rosenberg O, Roth Y, Kotler M, Zangen A, Dannon P. Deep
2002;70:1129–1139. transcranial magnetic stimulation for the treatment of audi-
28. Siebner HR, Rothwell J. Transcranial magnetic stimulation: tory hallucinations: a preliminary open-label study. Ann
new insights into representational cortical plasticity. Exp Gen Psychiatry. 2011;10:3.
Brain Res. 2003;148:1–16. 44. Semkovska M, McLoughlin DM. Objective cognitive perfor-
29. Wassermann EM. Risk and safety of repetitive transcranial mance associated with electroconvulsive therapy for depres-
magnetic stimulation: report and suggested guidelines from sion: a systematic review and meta-analysis. Biol Psychiatry.
the International Workshop on the Safety of Repetitive 2010;68:568–577.
Transcranial Magnetic Stimulation, June 5-7, 1996. 45. Grønli O, Stensland GØ, Wynn R, Olstad R. Neurotrophic
Electroencephalogr Clin Neurophysiol. 1996;108:1–16. factors in serum following ECT: a pilot study. World J Biol
30. Hoffman RE, Boutros NN, Berman RM, et al. Transcranial Psychiatry. 2009;10:295–301.
magnetic stimulation of left temporoparietal cortex in three 46. Young J, Murthy L, Westby M, Akunne A, O’Mahony R.
patients reporting hallucinated ‘‘voices’’. Biol Psychiatry. Guideline Development Group.Diagnosis, prevention, and
1999;46:130–132. management of delirium: summary of NICE guidance. Br
31. Aleman A, Sommer IEC, Kahn RS. Efficacy of slow repeti- Med J. 2010;341:c3704.
tive transcranial magnetic stimulation in the treatment of 47. Tharyan P, Adams CE. Electroconvulsive therapy for schizo-
phrenia. Cochrane Database Syst Rev. 2005;18:CD000076.
10 713
I. E. C. Sommer et al. Treatment of Auditory Hallucinations
62. Menon GJ, Rahman I, Menon SJ, Dutton GN. Complex vi- mortality in elderly male veterans with dementia? J Am Ger-
sual hallucinations in the visually impaired: the Charles Bon- iatr Soc. 2010;58:1027–1034.
net Syndrome. Surv Ophthalmol. 2003;48:58–72. 64. Meng Z, Liu S, Zheng Y, Phillips JS. Repetitive transcranial
63. Rossom RC, Rector TS, Lederle FA, Dysken MW. Are all magnetic stimulation for tinnitus. Cochrane Database Syst
commonly prescribed antipsychotics associated with greater Rev. 2011;(10): CD007946
714 11